Shen Lian Biomedical(688098)2024-04-26 09:31Financial Performance - The company's operating revenue for Q1 2024 was ¥88,058,162.67, representing a year-on-year increase of 7.58%[4] - The net profit attributable to shareholders was -¥2,209,184.73, a decrease of 113.92% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥2,869,254.06, down 121.23% year-on-year[4] - Total revenue for Q1 2024 was CNY 88,058,162.67, an increase of 7.3% compared to CNY 81,851,831.18 in Q1 2023[17] - Net profit for Q1 2024 was a loss of CNY 3,125,388.59, compared to a profit of CNY 15,867,632.60 in Q1 2023[19] - The basic and diluted earnings per share for Q1 2024 were both CNY -0.01, compared to CNY 0.04 in Q1 2023[19] Cash Flow - The net cash flow from operating activities was -¥24,404,381.56, not applicable for comparison[4] - Cash flow from operating activities was CNY 50,460,078.65 in Q1 2024, compared to CNY 33,979,285.31 in Q1 2023, indicating a 48.7% increase[21] - Net cash inflow from operating activities was -32,986,013.65 in the previous year, indicating an improvement[22] - The ending balance of cash and cash equivalents was 45,727,802.46 in the previous year[23] - The net increase in cash and cash equivalents was -6,818,173.45 in the previous year, showing a reduced decline[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,594,148,552.49, a slight increase of 0.01% from the end of the previous year[5] - As of March 31, 2024, the total current assets amounted to RMB 605,299,685.32, an increase from RMB 598,290,313.62 as of December 31, 2023, reflecting a growth of approximately 1.69%[14] - The total non-current assets were reported at RMB 646,043,036.12, down from RMB 658,334,632.32, showing a decrease of about 1.85%[14] - The total liabilities for Q1 2024 were CNY 90,205,966.26, an increase from CNY 86,926,310.95 in Q1 2023[16] - The equity attributable to shareholders decreased by 0.15% to ¥1,486,523,034.62 compared to the end of the previous year[5] - The company’s equity attributable to shareholders was CNY 1,486,523,034.62 in Q1 2024, down from CNY 1,488,732,219.35 in Q1 2023[16] Research and Development - Research and development expenses totaled ¥14,184,983.93, an increase of 26.04% compared to the previous year[4] - R&D expenses accounted for 16.11% of operating revenue, up 2.36 percentage points year-on-year[4] - The company reported a significant increase in research and development expenses, totaling CNY 12,646,826.27 in Q1 2024, compared to CNY 8,757,354.77 in Q1 2023, marking a 44.5% increase[18] - Increased sales and R&D expenses are attributed to the ongoing diversification strategy and the launch of new products in the market[7] Shareholding Structure - The top shareholder, Yang Yufang, holds 21.93% of the shares, totaling 90,063,197 shares, while the second-largest shareholder, UNITED BIOMEDICAL, INC., holds 10.52% with 43,199,898 shares[10] - The combined shareholding of the top ten shareholders accounts for 35.82%, indicating a concentrated ownership structure[11] - The company has not reported any significant changes in the shareholding structure or participation in margin trading activities during the reporting period[11] Operational Status - The company is expanding its product offerings with new vaccines and diagnostic products, which have begun to generate revenue[7] - There are no additional important reminders regarding the company's operational status during the reporting period[12]